Yifeng Pharmary(SH:603939) Huachuang Securities·2025-09-22 09:42Investment Rating - The report maintains a "Recommended" rating for the company, with a target price of 29.1 CNY, compared to the current price of 25.22 CNY [4][8]. Core Views - The company is facing revenue pressure but is focusing on cost reduction and efficiency improvements. In the first half of 2025, the company reported revenue of 11.72 billion CNY (down 0.3% year-on-year) and a net profit attributable to shareholders of 880 million CNY (up 10.3% year-on-year) [2][4]. - The revenue decline is attributed to the company's strategic decision to close low-efficiency stores and slow down the expansion of new stores, focusing instead on improving the quality of existing stores [2][4]. - The company has shown resilience in its operations despite industry pressures, with a projected net profit growth of 15% annually from 2025 to 2027 [2][4]. Financial Summary - Key financial indicators for the company are as follows: - Total revenue for 2024 is projected at 24.06 billion CNY, with a year-on-year growth rate of 6.5% - Net profit attributable to shareholders for 2024 is projected at 1.53 billion CNY, with a year-on-year growth rate of 8.3% - Earnings per share (EPS) for 2024 is expected to be 1.26 CNY, with a price-to-earnings (P/E) ratio of 20 [2][9]. - The company has a total market capitalization of 30.58 billion CNY and a debt-to-equity ratio of 54.84% [5][9]. Operational Insights - As of June 2025, the company operates a total of 14,701 stores, with 10,681 being directly operated (down 5.6% year-on-year) and 4,020 being franchise stores (up 17.3% year-on-year) [2][8]. - The company's retail business generated revenue of 10.20 billion CNY in the first half of 2025, with a gross margin of 42.0% [2][8]. - The company is also focusing on mergers and acquisitions, establishing a dedicated team for auditing and evaluating potential targets [2][8].